Par Drugs And Chemicals Limited
NSE: PAR · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Par Drugs And Chemicals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Par Drugs & Chemicals Ltd is an Indian manufacturer specialising in Active Pharmaceutical Ingredients (APIs) and fine chemicals. The company maintains a focused portfolio, particularly within the antacid molecules segment, serving both domestic and international markets.
Business Model
The company generates revenue through the manufacturing and sale of a specialised portfolio comprising 15 APIs and 10 fine chemicals. Its business model is centred on the production of antacid-related pharmaceutical ingredients for diverse client bases.
- API Portfolio:15
- Fine Chemicals Portfolio:10
Growth Outlook
Growth is driven by the company's established presence in the antacid molecules segment and its ability to cater to both domestic and export pharmaceutical markets.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical manufacturing regulations and quality standards that, if not met, could disrupt operations.
- Concentration Risk. A heavy reliance on the antacid molecules segment exposes the company to market fluctuations and demand shifts within that specific therapeutic category.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and raw materials can significantly impact profit margins.
- Export Market Sensitivity. Exposure to international markets introduces risks related to currency fluctuations, geopolitical instability, and varying international regulatory requirements.
Start your research today
Unlock AI insights, financials, peers and live data on Par Drugs And Chemicals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹104 Cr
TTM · standalone
NET PROFIT
₹13 Cr
TTM · standalone
EPS
₹10.65
TTM · standalone
RETURN ON EQUITY
12.8%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
16.4%
TTM · standalone
P/E
11.6x
Q4 FY26 · standalone
EV/EBITDA
5.7x
Q4 FY26 · standalone
EBITDA MARGIN
20.4%
TTM · standalone
NET PROFIT MARGIN
4.3%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Par Drugs And Chemicals LimitedPAR | ₹162 Cr | 11.64 | 5.70 | 2.7% | 20.4% | 12.8% | 16.4% | +17.5% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Par Drugs And Chemicals Limited
NSE: PAR · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Par Drugs And Chemicals Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Par Drugs & Chemicals Ltd is an Indian manufacturer specialising in Active Pharmaceutical Ingredients (APIs) and fine chemicals. The company maintains a focused portfolio, particularly within the antacid molecules segment, serving both domestic and international markets.
Business Model
The company generates revenue through the manufacturing and sale of a specialised portfolio comprising 15 APIs and 10 fine chemicals. Its business model is centred on the production of antacid-related pharmaceutical ingredients for diverse client bases.
- API Portfolio:15
- Fine Chemicals Portfolio:10
Growth Outlook
Growth is driven by the company's established presence in the antacid molecules segment and its ability to cater to both domestic and export pharmaceutical markets.
Key Risks
- Regulatory Compliance. The company is subject to stringent pharmaceutical manufacturing regulations and quality standards that, if not met, could disrupt operations.
- Concentration Risk. A heavy reliance on the antacid molecules segment exposes the company to market fluctuations and demand shifts within that specific therapeutic category.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and raw materials can significantly impact profit margins.
- Export Market Sensitivity. Exposure to international markets introduces risks related to currency fluctuations, geopolitical instability, and varying international regulatory requirements.
Start your research today
Unlock AI insights, financials, peers and live data on Par Drugs And Chemicals Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹104 Cr
TTM · standalone
NET PROFIT
₹13 Cr
TTM · standalone
EPS
₹10.65
TTM · standalone
RETURN ON EQUITY
12.8%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
16.4%
TTM · standalone
P/E
11.6x
Q4 FY26 · standalone
EV/EBITDA
5.7x
Q4 FY26 · standalone
EBITDA MARGIN
20.4%
TTM · standalone
NET PROFIT MARGIN
4.3%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26